Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura

Kidney International

Volumn 75, Issue SUPPL. 112, 2009, Pages

  Tsai, Han Mou ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

ADAMTS13; Shear stress; Thrombosis; Thrombotic thrombocytopenic purpura; Von Willebrand factor

Indexed keywords

AUTOANTIBODY; RITUXIMAB; TICLOPIDINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR;

AUTOIMMUNE DISEASE; CONFERENCE PAPER; DISEASE SEVERITY; EVOLUTIONARY ADAPTATION; GENDER; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KIDNEY FAILURE; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; SHEAR STRESS; THROMBOCYTE AGGREGATION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD; BLOOD CLOTTING; BLOOD COMPONENT THERAPY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; MICROCIRCULATION; PHENOTYPE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ADAM PROTEINS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BLOOD COAGULATION; BLOOD COMPONENT TRANSFUSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY FAILURE; MICROCIRCULATION; PHENOTYPE; PLASMA EXCHANGE; PLATELET AGGREGATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RISK FACTORS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 63049087674     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.610     Document Type: Conference Paper

References (50)

1. Bukowski RM. Thrombotic thrombocytopenic purpura. A review. Prog Hemost Thromb 1982; 6: 287-337.
2. Tsai HM. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am 2007; 21: 609-632.
3. Saunders RE, barrategui-Garrido C, Fremeaux-Bacchi V et al. The interactive factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and factor I mutations with structural models. Hum Mutat 2007; 28: 222-234.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
5. Siedlecki CA, Lestini BJ, Kottke-Marchant KK et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-2950.
6. Konstantopoulos K, Chow TW, Turner NA et al. Shear stress-induced binding of von Willebrand factor to platelets. Biorheology 1997; 34: 57-71.
7. Tsai HM. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. J Mol Med 2002; 80: 639-647.
8. Donadelli R, Orje JN, Capoferri C et al. Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood. Blood 2006; 107: 1943-1950.
9. Schneider SW, Nuschele S, Wixforth A et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci USA 2007; 104: 7899-7903.
10. Asada Y, Sumiyoshi A, Hayashi T et al. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic pupura, with special reference to factor VIII related antigen. Thromb Res 1985; 38: 467-479.
11. Tsai HM, Chandler WL, Sarode R et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001; 49: 653-659.
12. Tsai HM. The kidney in thrombotic thrombocytopenic purpura. Minerva Med 2007; 98: 731-747.
13. Chauhan AK, Walsh MT, Zhu G et al. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 2008; 111: 3452-3457.
14. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005; 3: 1710-1716.
15. Motto DG, Chauhan AK, Zhu G et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115: 2752-2761.
16. Romani DW, Fijnheer R, Brinkman HJ et al. Endothelial cell activation in thrombotic thrombocytopenic purpura (TTP): a prospective analysis. Br J Haematol 2003; 123: 522-527.
17. Shim K, Anderson PJ, Tuley EA et al. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 2008; 111: 651-657.
18. Cao W, Krishnaswamy S, Camire RM et al. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci USA 2008; 105: 7416-7421.
19. Zhou W, Dong L, Ginsburg D et al. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy? J Biol Chem 2005; 280: 39934-39941.
20. Luken BM, Turenhout EA, Kaijen PH et al. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost 2006; 96: 295-301.
21. Terrell DR, Williams LA, Vesely SK et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3: 1432-1436.
22. Tsai HM, Rice L, Sarode R et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2002; 132: 794-799.
23. Dong L, Chandrasekaran V, Zhou W et al. Evolution of ADAMTS13 antibodies in a patient with fatal thrombotic thrombocytopenic purpura. Am J Hematol 2008; 83: 815-817.
24. Lattuada A, Rossi E, Calzarossa C et al. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003; 88: 1029-1034.
25. Sanchez-Luceros A, Farias CE, Amaral MM et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 2004; 92: 1320-1326.
26. Allford SL, Harrison P, Lawrie AS et al. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol 2000; 111: 1215-1222.
27. Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 2001; 47: 387-392.
28. Zeigler ZR, Shadduck RK, Gryn JF et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apheresis 2001; 16: 19-22.
29. Rock G, Anderson D, Clark W et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005; 129: 79-86.
30. Yomtovian R, Niklinski W, Silver B et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124: 787-795.
31. George JN, Woodson RD, Kiss JE et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the transfusion medicine/hemostasis clinical trials network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apheresis 2006; 21: 49-56.
32. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore) 1981; 60: 413-428.
33. Vesely SK, George JN, Lammle B et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68.
34. Coppo P, Bengoufa D, Veyradier A et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004; 83: 233-244.
35. Zheng XL, Kaufman RM, Goodnough LT et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-4049.
36. Raife T, Atkinson B, Montgomery R et al. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004; 44: 146-150.
37. Noris M, Bucchioni S, Galbusera M et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005; 16: 1177-1183.
38. Assink K, Schiphorst R, Allford S et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003; 63: 1995-1999.
39. Schneppenheim R, Budde U, Oyen F et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003; 101: 1845-1850.
40. Matsumoto M, Yagi H, Ishizashi H et al. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004; 41: 68-74.
41. Veyradier A, Lavergne JM, Ribba AS et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2004; 2: 424-429.
42. Donadelli R, Banterla F, Galbusera M et al. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 96: 454-464.
43. Levy GG, Nichols WC, Lian EC et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
44. Pham PT, Danovitch GM, Wilkinson AH et al. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation 2002; 74: 1077-1080.
45. Ahmed S, Siddiqui AK, Chandrasekaran V. Correlation of thrombotic thrombocytopenic purpura disease activity with von Willibrand factor-cleaving protease level in ulcerative colitis. Am J Med 2004; 116: 786-787.
46. Zhou W, Inada M, Lee TP et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005; 85: 780-788.
47. Uemura M, Tatsumi K, Matsumoto M et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-924.
48. Shang D, Zheng XW, Niiya M et al. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006; 108: 2207-2215.
49. Turner N, Nolasco L, Tao Z et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006; 4: 1396-1404.
50. Manea M, Kristoffersson A, Schneppenheim R et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2007; 138: 651-662.